The global Direct Oral Anticoagulants (DOACs) market was valued at US$ 43840 million in 2023 and is anticipated to reach US$ 74650 million by 2030, witnessing a CAGR of 7.9% during the forecast period 2024-2030.

Direct Oral Anticoagulants (DOACs) Market

Direct oral anticoagulants (DOACs) are a class of medications used to prevent and treat blood clots by directly inhibiting specific enzymes involved in the clotting process.They include drugs that directly target either Factor Xa (such as rivaroxaban and apixaban) or thrombin (such as dabigatran), effectively reducing the risk of conditions like deep vein thrombosis, pulmonary embolism, and stroke in atrial fibrillation.

The market for Direct Oral Anticoagulants (DOACs) has experienced significant growth over the past decade. Initially introduced as alternatives to traditional anticoagulants like warfarin, DOACs offer advantages such as fixed dosing, fewer dietary restrictions, and minimal need for regular monitoring. The rising incidence of conditions such as atrial fibrillation and venous thromboembolism, coupled with an aging population, has driven increased demand for these medications. Consequently, the market has seen a surge in both prescription volume and the number of available DOACs.

In recent years, competition among pharmaceutical companies has intensified, leading to a broader range of DOAC options and potential price fluctuations. Major players like Bayer, Pfizer, and Bristol-Myers Squibb have continually advanced their products, seeking to differentiate through efficacy, safety profiles, and patient convenience. Additionally, the market has seen innovations such as the development of reversal agents for DOACs, addressing concerns over bleeding risks and enhancing the attractiveness of these drugs to both healthcare providers and patients.

Looking forward, the DOAC market is expected to continue its upward trajectory, driven by ongoing research, expanding indications, and increased global access. Emerging markets, where chronic diseases are rising alongside economic growth, present new opportunities for expansion. However, the market will also face challenges, including regulatory hurdles, potential generic competition, and the need for ongoing clinical trials to further establish long-term safety and efficacy. Overall, the DOAC market remains dynamic, with robust prospects shaped by evolving medical needs and technological advancements.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Direct Oral Anticoagulants (DOACs), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Direct Oral Anticoagulants (DOACs).

The Direct Oral Anticoagulants (DOACs) market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Direct Oral Anticoagulants (DOACs) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Direct Oral Anticoagulants (DOACs) manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Direct Oral Anticoagulants (DOACs) Market Report

Report Metric	Details
Report Name	Direct Oral Anticoagulants (DOACs) Market
Accounted market size in 2023	US$ 43840 million
Forecasted market size in 2030	US$ 74650 million
CAGR	7.9%
Base Year	2023
Forecasted years	2024 - 2030
Segment by Type	Oral Factor Xa Inhibitors Direct Thrombin Inhibitors (DTIs)
Segment by Application	Deep Vein Thrombosis Pulmonary Embolism Atrial Fibrillation Other
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Bristol Myers Squibb, Pfizer, Daiichi Sankyo, Janssen Pharmaceuticals, Bayer, Viatris, Boehringer Ingelheim, Accord Healthcare, Sandoz, Teva Pharmaceutical, Mylan, Apotex, GlaxoSmithKline
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Direct Oral Anticoagulants (DOACs) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Direct Oral Anticoagulants (DOACs) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

How fast is Direct Oral Anticoagulants (DOACs) Market growing?

Ans: The Direct Oral Anticoagulants (DOACs) Market witnessing a CAGR of 7.9% during the forecast period 2024-2030.

What is the Direct Oral Anticoagulants (DOACs) Market size in 2030?

Ans: The Direct Oral Anticoagulants (DOACs) Market size in 2030 will be US$ 74650 million.

Who are the main players in the Direct Oral Anticoagulants (DOACs) Market report?

Ans: The main players in the Direct Oral Anticoagulants (DOACs) Market are Bristol Myers Squibb, Pfizer, Daiichi Sankyo, Janssen Pharmaceuticals, Bayer, Viatris, Boehringer Ingelheim, Accord Healthcare, Sandoz, Teva Pharmaceutical, Mylan, Apotex, GlaxoSmithKline

What are the Application segmentation covered in the Direct Oral Anticoagulants (DOACs) Market report?

Ans: The Applications covered in the Direct Oral Anticoagulants (DOACs) Market report are Deep Vein Thrombosis, Pulmonary Embolism, Atrial Fibrillation, Other

What are the Type segmentation covered in the Direct Oral Anticoagulants (DOACs) Market report?

Ans: The Types covered in the Direct Oral Anticoagulants (DOACs) Market report are Oral Factor Xa Inhibitors, Direct Thrombin Inhibitors (DTIs)

1 Direct Oral Anticoagulants (DOACs) Market Overview

1.1 Product Definition

1.2 Direct Oral Anticoagulants (DOACs) by Type

1.2.1 Global Direct Oral Anticoagulants (DOACs) Market Value Comparison by Type (2024-2030)

1.2.2 Oral Factor Xa Inhibitors

1.2.3 Direct Thrombin Inhibitors (DTIs)

1.3 Direct Oral Anticoagulants (DOACs) by Application

1.3.1 Global Direct Oral Anticoagulants (DOACs) Market Value by Application (2024-2030)

1.3.2 Deep Vein Thrombosis

1.3.3 Pulmonary Embolism

1.3.4 Atrial Fibrillation

1.3.5 Other

1.4 Global Direct Oral Anticoagulants (DOACs) Market Size Estimates and Forecasts

1.4.1 Global Direct Oral Anticoagulants (DOACs) Revenue 2019-2030

1.4.2 Global Direct Oral Anticoagulants (DOACs) Sales 2019-2030

1.4.3 Global Direct Oral Anticoagulants (DOACs) Market Average Price (2019-2030)

1.5 Assumptions and Limitations

2 Direct Oral Anticoagulants (DOACs) Market Competition by Manufacturers

2.1 Global Direct Oral Anticoagulants (DOACs) Sales Market Share by Manufacturers (2019-2024)

2.2 Global Direct Oral Anticoagulants (DOACs) Revenue Market Share by Manufacturers (2019-2024)

2.3 Global Direct Oral Anticoagulants (DOACs) Average Price by Manufacturers (2019-2024)

2.4 Global Key Players of Direct Oral Anticoagulants (DOACs), Industry Ranking, 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Direct Oral Anticoagulants (DOACs), Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Direct Oral Anticoagulants (DOACs), Product Type & Application

2.7 Global Key Manufacturers of Direct Oral Anticoagulants (DOACs), Date of Enter into This Industry

2.8 Global Direct Oral Anticoagulants (DOACs) Market Competitive Situation and Trends

2.8.1 Global Direct Oral Anticoagulants (DOACs) Market Concentration Rate

2.8.2 The Global 5 and 10 Largest Direct Oral Anticoagulants (DOACs) Players Market Share by Revenue

2.8.3 Global Direct Oral Anticoagulants (DOACs) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global Direct Oral Anticoagulants (DOACs) Market Scenario by Region

3.1 Global Direct Oral Anticoagulants (DOACs) Market Size by Region: 2019 Versus 2023 Versus 2030

3.2 Global Direct Oral Anticoagulants (DOACs) Sales by Region: 2019-2030

3.2.1 Global Direct Oral Anticoagulants (DOACs) Sales by Region: 2019-2024

3.2.2 Global Direct Oral Anticoagulants (DOACs) Sales by Region: 2025-2030

3.3 Global Direct Oral Anticoagulants (DOACs) Revenue by Region: 2019-2030

3.3.1 Global Direct Oral Anticoagulants (DOACs) Revenue by Region: 2019-2024

3.3.2 Global Direct Oral Anticoagulants (DOACs) Revenue by Region: 2025-2030

3.4 North America Direct Oral Anticoagulants (DOACs) Market Facts & Figures by Country

3.4.1 North America Direct Oral Anticoagulants (DOACs) Market Size by Country: 2019 VS 2023 VS 2030

3.4.2 North America Direct Oral Anticoagulants (DOACs) Sales by Country (2019-2030)

3.4.3 North America Direct Oral Anticoagulants (DOACs) Revenue by Country (2019-2030)

3.4.4 United States

3.4.5 Canada

3.5 Europe Direct Oral Anticoagulants (DOACs) Market Facts & Figures by Country

3.5.1 Europe Direct Oral Anticoagulants (DOACs) Market Size by Country: 2019 VS 2023 VS 2030

3.5.2 Europe Direct Oral Anticoagulants (DOACs) Sales by Country (2019-2030)

3.5.3 Europe Direct Oral Anticoagulants (DOACs) Revenue by Country (2019-2030)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Direct Oral Anticoagulants (DOACs) Market Facts & Figures by Region

3.6.1 Asia Pacific Direct Oral Anticoagulants (DOACs) Market Size by Region: 2019 VS 2023 VS 2030

3.6.2 Asia Pacific Direct Oral Anticoagulants (DOACs) Sales by Region (2019-2030)

3.6.3 Asia Pacific Direct Oral Anticoagulants (DOACs) Revenue by Region (2019-2030)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Southeast Asia

3.7 Latin America Direct Oral Anticoagulants (DOACs) Market Facts & Figures by Country

3.7.1 Latin America Direct Oral Anticoagulants (DOACs) Market Size by Country: 2019 VS 2023 VS 2030

3.7.2 Latin America Direct Oral Anticoagulants (DOACs) Sales by Country (2019-2030)

3.7.3 Latin America Direct Oral Anticoagulants (DOACs) Revenue by Country

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.7.7 Colombia

3.8 Middle East and Africa Direct Oral Anticoagulants (DOACs) Market Facts & Figures by Country

3.8.1 Middle East and Africa Direct Oral Anticoagulants (DOACs) Market Size by Country: 2019 VS 2023 VS 2030

3.8.2 Middle East and Africa Direct Oral Anticoagulants (DOACs) Sales by Country (2019-2030)

3.8.3 Middle East and Africa Direct Oral Anticoagulants (DOACs) Revenue by Country

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global Direct Oral Anticoagulants (DOACs) Sales by Type (2019-2030)

4.1.1 Global Direct Oral Anticoagulants (DOACs) Sales by Type (2019-2024)

4.1.2 Global Direct Oral Anticoagulants (DOACs) Sales by Type (2025-2030)

4.1.3 Global Direct Oral Anticoagulants (DOACs) Sales Market Share by Type (2019-2030)

4.2 Global Direct Oral Anticoagulants (DOACs) Revenue by Type (2019-2030)

4.2.1 Global Direct Oral Anticoagulants (DOACs) Revenue by Type (2019-2024)

4.2.2 Global Direct Oral Anticoagulants (DOACs) Revenue by Type (2025-2030)

4.2.3 Global Direct Oral Anticoagulants (DOACs) Revenue Market Share by Type (2019-2030)

4.3 Global Direct Oral Anticoagulants (DOACs) Price by Type (2019-2030)

5 Segment by Application

5.1 Global Direct Oral Anticoagulants (DOACs) Sales by Application (2019-2030)

5.1.1 Global Direct Oral Anticoagulants (DOACs) Sales by Application (2019-2024)

5.1.2 Global Direct Oral Anticoagulants (DOACs) Sales by Application (2025-2030)

5.1.3 Global Direct Oral Anticoagulants (DOACs) Sales Market Share by Application (2019-2030)

5.2 Global Direct Oral Anticoagulants (DOACs) Revenue by Application (2019-2030)

5.2.1 Global Direct Oral Anticoagulants (DOACs) Revenue by Application (2019-2024)

5.2.2 Global Direct Oral Anticoagulants (DOACs) Revenue by Application (2025-2030)

5.2.3 Global Direct Oral Anticoagulants (DOACs) Revenue Market Share by Application (2019-2030)

5.3 Global Direct Oral Anticoagulants (DOACs) Price by Application (2019-2030)

6 Key Companies Profiled

6.1 Bristol Myers Squibb

6.1.1 Bristol Myers Squibb Company Information

6.1.2 Bristol Myers Squibb Description and Business Overview

6.1.3 Bristol Myers Squibb Direct Oral Anticoagulants (DOACs) Sales, Revenue and Gross Margin (2019-2024)

6.1.4 Bristol Myers Squibb Direct Oral Anticoagulants (DOACs) Product Portfolio

6.1.5 Bristol Myers Squibb Recent Developments/Updates

6.2 Pfizer

6.2.1 Pfizer Company Information

6.2.2 Pfizer Description and Business Overview

6.2.3 Pfizer Direct Oral Anticoagulants (DOACs) Sales, Revenue and Gross Margin (2019-2024)

6.2.4 Pfizer Direct Oral Anticoagulants (DOACs) Product Portfolio

6.2.5 Pfizer Recent Developments/Updates

6.3 Daiichi Sankyo

6.3.1 Daiichi Sankyo Company Information

6.3.2 Daiichi Sankyo Description and Business Overview

6.3.3 Daiichi Sankyo Direct Oral Anticoagulants (DOACs) Sales, Revenue and Gross Margin (2019-2024)

6.3.4 Daiichi Sankyo Direct Oral Anticoagulants (DOACs) Product Portfolio

6.3.5 Daiichi Sankyo Recent Developments/Updates

6.4 Janssen Pharmaceuticals

6.4.1 Janssen Pharmaceuticals Company Information

6.4.2 Janssen Pharmaceuticals Description and Business Overview

6.4.3 Janssen Pharmaceuticals Direct Oral Anticoagulants (DOACs) Sales, Revenue and Gross Margin (2019-2024)

6.4.4 Janssen Pharmaceuticals Direct Oral Anticoagulants (DOACs) Product Portfolio

6.4.5 Janssen Pharmaceuticals Recent Developments/Updates

6.5 Bayer

6.5.1 Bayer Company Information

6.5.2 Bayer Description and Business Overview

6.5.3 Bayer Direct Oral Anticoagulants (DOACs) Sales, Revenue and Gross Margin (2019-2024)

6.5.4 Bayer Direct Oral Anticoagulants (DOACs) Product Portfolio

6.5.5 Bayer Recent Developments/Updates

6.6 Viatris

6.6.1 Viatris Company Information

6.6.2 Viatris Description and Business Overview

6.6.3 Viatris Direct Oral Anticoagulants (DOACs) Sales, Revenue and Gross Margin (2019-2024)

6.6.4 Viatris Direct Oral Anticoagulants (DOACs) Product Portfolio

6.6.5 Viatris Recent Developments/Updates

6.7 Boehringer Ingelheim

6.7.1 Boehringer Ingelheim Company Information

6.7.2 Boehringer Ingelheim Description and Business Overview

6.7.3 Boehringer Ingelheim Direct Oral Anticoagulants (DOACs) Sales, Revenue and Gross Margin (2019-2024)

6.7.4 Boehringer Ingelheim Direct Oral Anticoagulants (DOACs) Product Portfolio

6.7.5 Boehringer Ingelheim Recent Developments/Updates

6.8 Accord Healthcare

6.8.1 Accord Healthcare Company Information

6.8.2 Accord Healthcare Description and Business Overview

6.8.3 Accord Healthcare Direct Oral Anticoagulants (DOACs) Sales, Revenue and Gross Margin (2019-2024)

6.8.4 Accord Healthcare Direct Oral Anticoagulants (DOACs) Product Portfolio

6.8.5 Accord Healthcare Recent Developments/Updates

6.9 Sandoz

6.9.1 Sandoz Company Information

6.9.2 Sandoz Description and Business Overview

6.9.3 Sandoz Direct Oral Anticoagulants (DOACs) Sales, Revenue and Gross Margin (2019-2024)

6.9.4 Sandoz Direct Oral Anticoagulants (DOACs) Product Portfolio

6.9.5 Sandoz Recent Developments/Updates

6.10 Teva Pharmaceutical

6.10.1 Teva Pharmaceutical Company Information

6.10.2 Teva Pharmaceutical Description and Business Overview

6.10.3 Teva Pharmaceutical Direct Oral Anticoagulants (DOACs) Sales, Revenue and Gross Margin (2019-2024)

6.10.4 Teva Pharmaceutical Direct Oral Anticoagulants (DOACs) Product Portfolio

6.10.5 Teva Pharmaceutical Recent Developments/Updates

6.11 Mylan

6.11.1 Mylan Company Information

6.11.2 Mylan Description and Business Overview

6.11.3 Mylan Direct Oral Anticoagulants (DOACs) Sales, Revenue and Gross Margin (2019-2024)

6.11.4 Mylan Direct Oral Anticoagulants (DOACs) Product Portfolio

6.11.5 Mylan Recent Developments/Updates

6.12 Apotex

6.12.1 Apotex Company Information

6.12.2 Apotex Description and Business Overview

6.12.3 Apotex Direct Oral Anticoagulants (DOACs) Sales, Revenue and Gross Margin (2019-2024)

6.12.4 Apotex Direct Oral Anticoagulants (DOACs) Product Portfolio

6.12.5 Apotex Recent Developments/Updates

6.13 GlaxoSmithKline

6.13.1 GlaxoSmithKline Company Information

6.13.2 GlaxoSmithKline Description and Business Overview

6.13.3 GlaxoSmithKline Direct Oral Anticoagulants (DOACs) Sales, Revenue and Gross Margin (2019-2024)

6.13.4 GlaxoSmithKline Direct Oral Anticoagulants (DOACs) Product Portfolio

6.13.5 GlaxoSmithKline Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Direct Oral Anticoagulants (DOACs) Industry Chain Analysis

7.2 Direct Oral Anticoagulants (DOACs) Key Raw Materials

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Direct Oral Anticoagulants (DOACs) Production Mode & Process

7.4 Direct Oral Anticoagulants (DOACs) Sales and Marketing

7.4.1 Direct Oral Anticoagulants (DOACs) Sales Channels

7.4.2 Direct Oral Anticoagulants (DOACs) Distributors

7.5 Direct Oral Anticoagulants (DOACs) Customers

8 Direct Oral Anticoagulants (DOACs) Market Dynamics

8.1 Direct Oral Anticoagulants (DOACs) Industry Trends

8.2 Direct Oral Anticoagulants (DOACs) Market Drivers

8.3 Direct Oral Anticoagulants (DOACs) Market Challenges

8.4 Direct Oral Anticoagulants (DOACs) Market Restraints

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Bristol–Myers Squibb

Pfizer Inc

Daiichi Sankyo

Janssen Pharmaceuticals

List of Tables

Table 1. Global Direct Oral Anticoagulants (DOACs) Market Value Comparison by Type (2024-2030) & (US$ Million)

Table 2. Global Direct Oral Anticoagulants (DOACs) Market Value by Application (2024-2030) & (US$ Million)

Table 3. Global Direct Oral Anticoagulants (DOACs) Market Competitive Situation by Manufacturers in 2023

Table 4. Global Direct Oral Anticoagulants (DOACs) Sales (K Units) of Key Manufacturers (2019-2024)

Table 5. Global Direct Oral Anticoagulants (DOACs) Sales Market Share by Manufacturers (2019-2024)

Table 6. Global Direct Oral Anticoagulants (DOACs) Revenue (US$ Million) by Manufacturers (2019-2024)

Table 7. Global Direct Oral Anticoagulants (DOACs) Revenue Share by Manufacturers (2019-2024)

Table 8. Global Market Direct Oral Anticoagulants (DOACs) Average Price (US$/Unit) of Key Manufacturers (2019-2024)

Table 9. Global Key Players of Direct Oral Anticoagulants (DOACs), Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Direct Oral Anticoagulants (DOACs), Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Direct Oral Anticoagulants (DOACs), Product Type & Application

Table 12. Global Key Manufacturers of Direct Oral Anticoagulants (DOACs), Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Direct Oral Anticoagulants (DOACs) by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Direct Oral Anticoagulants (DOACs) as of 2023)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Direct Oral Anticoagulants (DOACs) Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 17. Global Direct Oral Anticoagulants (DOACs) Sales by Region (2019-2024) & (K Units)

Table 18. Global Direct Oral Anticoagulants (DOACs) Sales Market Share by Region (2019-2024)

Table 19. Global Direct Oral Anticoagulants (DOACs) Sales by Region (2025-2030) & (K Units)

Table 20. Global Direct Oral Anticoagulants (DOACs) Sales Market Share by Region (2025-2030)

Table 21. Global Direct Oral Anticoagulants (DOACs) Revenue by Region (2019-2024) & (US$ Million)

Table 22. Global Direct Oral Anticoagulants (DOACs) Revenue Market Share by Region (2019-2024)

Table 23. Global Direct Oral Anticoagulants (DOACs) Revenue by Region (2025-2030) & (US$ Million)

Table 24. Global Direct Oral Anticoagulants (DOACs) Revenue Market Share by Region (2025-2030)

Table 25. North America Direct Oral Anticoagulants (DOACs) Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 26. North America Direct Oral Anticoagulants (DOACs) Sales by Country (2019-2024) & (K Units)

Table 27. North America Direct Oral Anticoagulants (DOACs) Sales by Country (2025-2030) & (K Units)

Table 28. North America Direct Oral Anticoagulants (DOACs) Revenue by Country (2019-2024) & (US$ Million)

Table 29. North America Direct Oral Anticoagulants (DOACs) Revenue by Country (2025-2030) & (US$ Million)

Table 30. Europe Direct Oral Anticoagulants (DOACs) Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 31. Europe Direct Oral Anticoagulants (DOACs) Sales by Country (2019-2024) & (K Units)

Table 32. Europe Direct Oral Anticoagulants (DOACs) Sales by Country (2025-2030) & (K Units)

Table 33. Europe Direct Oral Anticoagulants (DOACs) Revenue by Country (2019-2024) & (US$ Million)

Table 34. Europe Direct Oral Anticoagulants (DOACs) Revenue by Country (2025-2030) & (US$ Million)

Table 35. Asia Pacific Direct Oral Anticoagulants (DOACs) Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 36. Asia Pacific Direct Oral Anticoagulants (DOACs) Sales by Region (2019-2024) & (K Units)

Table 37. Asia Pacific Direct Oral Anticoagulants (DOACs) Sales by Region (2025-2030) & (K Units)

Table 38. Asia Pacific Direct Oral Anticoagulants (DOACs) Revenue by Region (2019-2024) & (US$ Million)

Table 39. Asia Pacific Direct Oral Anticoagulants (DOACs) Revenue by Region (2025-2030) & (US$ Million)

Table 40. Latin America Direct Oral Anticoagulants (DOACs) Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 41. Latin America Direct Oral Anticoagulants (DOACs) Sales by Country (2019-2024) & (K Units)

Table 42. Latin America Direct Oral Anticoagulants (DOACs) Sales by Country (2025-2030) & (K Units)

Table 43. Latin America Direct Oral Anticoagulants (DOACs) Revenue by Country (2019-2024) & (US$ Million)

Table 44. Latin America Direct Oral Anticoagulants (DOACs) Revenue Market Share by Country (2019-2024)

Table 45. Middle East and Africa Direct Oral Anticoagulants (DOACs) Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 46. Middle East and Africa Direct Oral Anticoagulants (DOACs) Sales by Country (2019-2024) & (K Units)

Table 47. Middle East and Africa Direct Oral Anticoagulants (DOACs) Sales by Country (2025-2030) & (K Units)

Table 48. Middle East and Africa Direct Oral Anticoagulants (DOACs) Revenue by Country (2019-2024) & (US$ Million)

Table 49. Middle East and Africa Direct Oral Anticoagulants (DOACs) Revenue by Country (2025-2030) & (US$ Million)

Table 50. Global Direct Oral Anticoagulants (DOACs) Sales (K Units) by Type (2019-2024)

Table 51. Global Direct Oral Anticoagulants (DOACs) Sales (K Units) by Type (2025-2030)

Table 52. Global Direct Oral Anticoagulants (DOACs) Sales Market Share by Type (2019-2024)

Table 53. Global Direct Oral Anticoagulants (DOACs) Sales Market Share by Type (2025-2030)

Table 54. Global Direct Oral Anticoagulants (DOACs) Revenue (US$ Million) by Type (2019-2024)

Table 55. Global Direct Oral Anticoagulants (DOACs) Revenue (US$ Million) by Type (2025-2030)

Table 56. Global Direct Oral Anticoagulants (DOACs) Revenue Market Share by Type (2019-2024)

Table 57. Global Direct Oral Anticoagulants (DOACs) Revenue Market Share by Type (2025-2030)

Table 58. Global Direct Oral Anticoagulants (DOACs) Price (US$/Unit) by Type (2019-2024)

Table 59. Global Direct Oral Anticoagulants (DOACs) Price (US$/Unit) by Type (2025-2030)

Table 60. Global Direct Oral Anticoagulants (DOACs) Sales (K Units) by Application (2019-2024)

Table 61. Global Direct Oral Anticoagulants (DOACs) Sales (K Units) by Application (2025-2030)

Table 62. Global Direct Oral Anticoagulants (DOACs) Sales Market Share by Application (2019-2024)

Table 63. Global Direct Oral Anticoagulants (DOACs) Sales Market Share by Application (2025-2030)

Table 64. Global Direct Oral Anticoagulants (DOACs) Revenue (US$ Million) by Application (2019-2024)

Table 65. Global Direct Oral Anticoagulants (DOACs) Revenue (US$ Million) by Application (2025-2030)

Table 66. Global Direct Oral Anticoagulants (DOACs) Revenue Market Share by Application (2019-2024)

Table 67. Global Direct Oral Anticoagulants (DOACs) Revenue Market Share by Application (2025-2030)

Table 68. Global Direct Oral Anticoagulants (DOACs) Price (US$/Unit) by Application (2019-2024)

Table 69. Global Direct Oral Anticoagulants (DOACs) Price (US$/Unit) by Application (2025-2030)

Table 70. Bristol Myers Squibb Company Information

Table 71. Bristol Myers Squibb Description and Business Overview

Table 72. Bristol Myers Squibb Direct Oral Anticoagulants (DOACs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 73. Bristol Myers Squibb Direct Oral Anticoagulants (DOACs) Product

Table 74. Bristol Myers Squibb Recent Developments/Updates

Table 75. Pfizer Company Information

Table 76. Pfizer Description and Business Overview

Table 77. Pfizer Direct Oral Anticoagulants (DOACs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 78. Pfizer Direct Oral Anticoagulants (DOACs) Product

Table 79. Pfizer Recent Developments/Updates

Table 80. Daiichi Sankyo Company Information

Table 81. Daiichi Sankyo Description and Business Overview

Table 82. Daiichi Sankyo Direct Oral Anticoagulants (DOACs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 83. Daiichi Sankyo Direct Oral Anticoagulants (DOACs) Product

Table 84. Daiichi Sankyo Recent Developments/Updates

Table 85. Janssen Pharmaceuticals Company Information

Table 86. Janssen Pharmaceuticals Description and Business Overview

Table 87. Janssen Pharmaceuticals Direct Oral Anticoagulants (DOACs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 88. Janssen Pharmaceuticals Direct Oral Anticoagulants (DOACs) Product

Table 89. Janssen Pharmaceuticals Recent Developments/Updates

Table 90. Bayer Company Information

Table 91. Bayer Description and Business Overview

Table 92. Bayer Direct Oral Anticoagulants (DOACs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 93. Bayer Direct Oral Anticoagulants (DOACs) Product

Table 94. Bayer Recent Developments/Updates

Table 95. Viatris Company Information

Table 96. Viatris Description and Business Overview

Table 97. Viatris Direct Oral Anticoagulants (DOACs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 98. Viatris Direct Oral Anticoagulants (DOACs) Product

Table 99. Viatris Recent Developments/Updates

Table 100. Boehringer Ingelheim Company Information

Table 101. Boehringer Ingelheim Description and Business Overview

Table 102. Boehringer Ingelheim Direct Oral Anticoagulants (DOACs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 103. Boehringer Ingelheim Direct Oral Anticoagulants (DOACs) Product

Table 104. Boehringer Ingelheim Recent Developments/Updates

Table 105. Accord Healthcare Company Information

Table 106. Accord Healthcare Description and Business Overview

Table 107. Accord Healthcare Direct Oral Anticoagulants (DOACs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 108. Accord Healthcare Direct Oral Anticoagulants (DOACs) Product

Table 109. Accord Healthcare Recent Developments/Updates

Table 110. Sandoz Company Information

Table 111. Sandoz Description and Business Overview

Table 112. Sandoz Direct Oral Anticoagulants (DOACs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 113. Sandoz Direct Oral Anticoagulants (DOACs) Product

Table 114. Sandoz Recent Developments/Updates

Table 115. Teva Pharmaceutical Company Information

Table 116. Teva Pharmaceutical Description and Business Overview

Table 117. Teva Pharmaceutical Direct Oral Anticoagulants (DOACs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 118. Teva Pharmaceutical Direct Oral Anticoagulants (DOACs) Product

Table 119. Teva Pharmaceutical Recent Developments/Updates

Table 120. Mylan Company Information

Table 121. Mylan Description and Business Overview

Table 122. Mylan Direct Oral Anticoagulants (DOACs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 123. Mylan Direct Oral Anticoagulants (DOACs) Product

Table 124. Mylan Recent Developments/Updates

Table 125. Apotex Company Information

Table 126. Apotex Description and Business Overview

Table 127. Apotex Direct Oral Anticoagulants (DOACs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 128. Apotex Direct Oral Anticoagulants (DOACs) Product

Table 129. Apotex Recent Developments/Updates

Table 130. GlaxoSmithKline Company Information

Table 131. GlaxoSmithKline Description and Business Overview

Table 132. GlaxoSmithKline Direct Oral Anticoagulants (DOACs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 133. GlaxoSmithKline Direct Oral Anticoagulants (DOACs) Product

Table 134. GlaxoSmithKline Recent Developments/Updates

Table 135. Key Raw Materials Lists

Table 136. Raw Materials Key Suppliers Lists

Table 137. Direct Oral Anticoagulants (DOACs) Distributors List

Table 138. Direct Oral Anticoagulants (DOACs) Customers List

Table 139. Direct Oral Anticoagulants (DOACs) Market Trends

Table 140. Direct Oral Anticoagulants (DOACs) Market Drivers

Table 141. Direct Oral Anticoagulants (DOACs) Market Challenges

Table 142. Direct Oral Anticoagulants (DOACs) Market Restraints

Table 143. Research Programs/Design for This Report

Table 144. Key Data Information from Secondary Sources

Table 145. Key Data Information from Primary Sources

Table 146. Authors List of This Report

List of Figures

Figure 1. Product Picture of Direct Oral Anticoagulants (DOACs)

Figure 2. Global Direct Oral Anticoagulants (DOACs) Market Value Comparison by Type (2024-2030) & (US$ Million)

Figure 3. Global Direct Oral Anticoagulants (DOACs) Market Share by Type: 2023 & 2030

Figure 4. Oral Factor Xa Inhibitors Product Picture

Figure 5. Direct Thrombin Inhibitors (DTIs) Product Picture

Figure 6. Global Direct Oral Anticoagulants (DOACs) Market Value by Application (2024-2030) & (US$ Million)

Figure 7. Global Direct Oral Anticoagulants (DOACs) Market Share by Application: 2023 & 2030

Figure 8. Deep Vein Thrombosis

Figure 9. Pulmonary Embolism

Figure 10. Atrial Fibrillation

Figure 11. Other

Figure 12. Global Direct Oral Anticoagulants (DOACs) Revenue, (US$ Million), 2019 VS 2023 VS 2030

Figure 13. Global Direct Oral Anticoagulants (DOACs) Market Size (2019-2030) & (US$ Million)

Figure 14. Global Direct Oral Anticoagulants (DOACs) Sales (2019-2030) & (K Units)

Figure 15. Global Direct Oral Anticoagulants (DOACs) Average Price (US$/Unit) & (2019-2030)

Figure 16. Direct Oral Anticoagulants (DOACs) Report Years Considered

Figure 17. Direct Oral Anticoagulants (DOACs) Sales Share by Manufacturers in 2023

Figure 18. Global Direct Oral Anticoagulants (DOACs) Revenue Share by Manufacturers in 2023

Figure 19. Global 5 and 10 Largest Direct Oral Anticoagulants (DOACs) Players: Market Share by Revenue in Direct Oral Anticoagulants (DOACs) in 2023

Figure 20. Direct Oral Anticoagulants (DOACs) Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 21. Global Direct Oral Anticoagulants (DOACs) Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Figure 22. North America Direct Oral Anticoagulants (DOACs) Sales Market Share by Country (2019-2030)

Figure 23. North America Direct Oral Anticoagulants (DOACs) Revenue Market Share by Country (2019-2030)

Figure 24. United States Direct Oral Anticoagulants (DOACs) Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 25. Canada Direct Oral Anticoagulants (DOACs) Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 26. Europe Direct Oral Anticoagulants (DOACs) Sales Market Share by Country (2019-2030)

Figure 27. Europe Direct Oral Anticoagulants (DOACs) Revenue Market Share by Country (2019-2030)

Figure 28. Germany Direct Oral Anticoagulants (DOACs) Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 29. France Direct Oral Anticoagulants (DOACs) Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 30. U.K. Direct Oral Anticoagulants (DOACs) Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 31. Italy Direct Oral Anticoagulants (DOACs) Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 32. Russia Direct Oral Anticoagulants (DOACs) Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 33. Asia Pacific Direct Oral Anticoagulants (DOACs) Sales Market Share by Region (2019-2030)

Figure 34. Asia Pacific Direct Oral Anticoagulants (DOACs) Revenue Market Share by Region (2019-2030)

Figure 35. China Direct Oral Anticoagulants (DOACs) Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 36. Japan Direct Oral Anticoagulants (DOACs) Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 37. South Korea Direct Oral Anticoagulants (DOACs) Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 38. India Direct Oral Anticoagulants (DOACs) Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 39. Australia Direct Oral Anticoagulants (DOACs) Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 40. China Taiwan Direct Oral Anticoagulants (DOACs) Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 41. Southeast Asia Direct Oral Anticoagulants (DOACs) Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 42. Latin America Direct Oral Anticoagulants (DOACs) Sales Market Share by Country (2019-2030)

Figure 43. Mexico Direct Oral Anticoagulants (DOACs) Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 44. Brazil Direct Oral Anticoagulants (DOACs) Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 45. Argentina Direct Oral Anticoagulants (DOACs) Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 46. Colombia Direct Oral Anticoagulants (DOACs) Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 47. Middle East and Africa Direct Oral Anticoagulants (DOACs) Sales Market Share by Country (2019-2030)

Figure 48. Middle East and Africa Direct Oral Anticoagulants (DOACs) Revenue Market Share by Country (2019-2030)

Figure 49. Turkey Direct Oral Anticoagulants (DOACs) Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 50. Saudi Arabia Direct Oral Anticoagulants (DOACs) Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 51. UAE Direct Oral Anticoagulants (DOACs) Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 52. Global Sales Market Share of Direct Oral Anticoagulants (DOACs) by Type (2019-2030)

Figure 53. Global Revenue Market Share of Direct Oral Anticoagulants (DOACs) by Type (2019-2030)

Figure 54. Global Direct Oral Anticoagulants (DOACs) Price (US$/Unit) by Type (2019-2030)

Figure 55. Global Sales Market Share of Direct Oral Anticoagulants (DOACs) by Application (2019-2030)

Figure 56. Global Revenue Market Share of Direct Oral Anticoagulants (DOACs) by Application (2019-2030)

Figure 57. Global Direct Oral Anticoagulants (DOACs) Price (US$/Unit) by Application (2019-2030)

Figure 58. Direct Oral Anticoagulants (DOACs) Value Chain

Figure 59. Direct Oral Anticoagulants (DOACs) Production Process

Figure 60. Channels of Distribution (Direct Vs Distribution)

Figure 61. Bottom-up and Top-down Approaches for This Report

Figure 62. Data Triangulation

Figure 63. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions